Amonafide malate

Drug Profile

Amonafide malate

Alternative Names: Amonafide L-malate; Amonafide maleate; AS 1413; Xanafide

Latest Information Update: 02 Feb 2011

Price : $50

At a glance

  • Originator Xanthus Pharmaceuticals
  • Developer Antisoma; Xanthus Pharmaceuticals
  • Class Antineoplastics; Isoquinolines; Naphthalimides; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Prostate cancer

Most Recent Events

  • 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Australia (IV)
  • 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Canada (IV)
  • 31 Jan 2011 Discontinued - Phase-III for Acute myeloid leukaemia in Eastern Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top